

## *Lavandula angustifolia* Effects on Rat Models of Alzheimer's Disease Through the Investigation of Serum Metabolic Features Using NMR Metabolomics

Afsaneh Arefi Oskouie<sup>1\*</sup>, Reyhaneh Farrokhi Yekta<sup>1,2</sup>, Mostafa Rezaei Tavirani<sup>2</sup>, Masoud Soheili Kashani<sup>1,2</sup>, and Fatemeh Goshadrou<sup>1</sup>

1. Department of Basic Sciences, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2. Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

### Abstract

**Background:** Alzheimer's Disease (AD) is the most prevalent cause of memory impairment in the elderly population, but the diagnosis and treatment of the disease is still challenging. Lavender aqueous extract has recently been shown to have the potential in clearing Amyloid-beta plaques from AD rat hippocampus. To elucidate the therapeutic mechanisms of lavender, serum metabolic fingerprint of A $\beta$ -induced rat Alzheimer's models was investigated through nuclear magnetic resonance spectrometry.

**Methods:** For the establishment of rat Alzheimer's models, 10  $\mu$ g of Amyloid beta 1-42 was injected to male Wistar rats. The lavender aqueous extract was injected 20 days after the establishment of the models, once daily for 20 days. Serum samples were collected and metabolite fingerprints were obtained using 500 MHz <sup>1</sup>H-NMR spectrometry, following multivariate statistical analyses. The resulted metabolites were then subjected to pathway analysis tools to reveal metabolic pathways affected by the lavender extract treatment.

**Results:** Levels of 10 metabolite markers including alanine, glutamine, serine, isoleucine, valine, carnitine, isobutyrate, pantothenate, glucose and asparagine were reversed nearly to control values after treatment with lavender extract. The results revealed that the most significantly affected pathways during treatment with lavender extract belonged to carbohydrate and amino acid metabolism, including pantothenate and CoA metabolism, glyoxilate and dicarboxylate metabolism, alanine, aspartate and glutamate metabolism, cysteine and methionine metabolism.

**Conclusion:** As lavender extract reversed the direction of changes of some metabolites involved in AD pathogenesis, it was concluded that the extract might play a role in the disease improvement and serve as a potential therapeutic option for the treatment of AD. Moreover, the metabolites which were found in AD rats could serve as a potential marker panel for the disease; however, much further investigation and validation of the results is needed.


*Avicenna J Med Biotech 2018; 10(2): 83-92*

**Keywords:** Alzheimer disease, *Lavandula*, Metabolomics, Serum

### Introduction

Alzheimer's Disease (AD), a multifactorial neurodegenerative disorder, is the most prevalent cause of progressive loss of memory and cognitive impairments in elderly people<sup>1-3</sup>. Various environmental and gen-etic factors are involved in AD pathogenesis, one of the most important ones is oxidative stress<sup>4</sup>. Accurate and reliable diagnosis of AD can just be done by post-mortem examination of brain tissue samples based on the presence of Amyloid beta (A $\beta$ ) and neurofibrillary

tangles and hyper-phosphorylation of tau protein<sup>5</sup>. Currently, the most reliable body fluid for AD screening is the Cerebrospinal Fluid (CSF), which has its own challenges, especially in gathering method, lumbar puncture, which is still considered a relatively invasive collecting method and causes patient's discomfort<sup>6</sup>. It is estimated that about 500 ml of CSF is secreted into blood daily, making blood a suitable source of biomarkers for neurodegenerative diseases like AD



7. Thus, efforts are in progress to find novel valid markers in blood plasma or serum samples. Moreover, early detection of AD, is still a great challenge because the disease starts about 20 years or more before the emergence of the clinical symptoms. There are still no effective approaches for the treatment of AD. The most currently used drugs include Donepezil, Galantamine, Rivastigmine, and Memantine. These drugs act as acetylcholine esterase inhibitors, which improve the ability of the impaired nerves to transmit messages or as NMDA (N-methyl-D-aspartate) receptor antagonists, which regulate the activity of glutamate as an important neurotransmitter in learning and memory<sup>8,9</sup>.

In the past decades, herbal compounds have proven to be effective treatments for different diseases including AD<sup>4,10-12</sup>. The effect of these compounds on slowing the disease progression can be elucidated through metabolomic approaches which reveal the alterations in small molecule metabolites (<1500 Da) in the system under study<sup>13</sup>. These herbal medicines have antioxidant and anti-inflammatory properties as can be seen in compounds such as *Ginkgo biloba*<sup>14,15</sup>. Metabolic pathways are conserved through evolution and they have the highest levels of similarity between humans and rodents.

Pathway analysis of metabolomics data can propose mechanisms of actions of the herbal treatments. *Lavandula angustifolia* (lavender), a species from Lamiaceae family, is a plant with small purplish flowers which are mostly used to produce aromatic extracts<sup>16</sup>. Previous phytochemical studies demonstrated that the most effective components of the aerial parts of lavender are monoterpenes linalool and linalyl acetate, coumarins and triterpenoids which cause its pharmacological activity<sup>17-19</sup>. It also contains aqueous phenolic compounds, such as hydroxycinnamic acids and flavone glycosides which are associated with its antioxidant activity<sup>20</sup>. Various pharmacological properties are attributed to lavender extract including anticonvulsant, sedative, analgesic, antioxidant and local anesthetic activity<sup>21-24</sup>.

In a recent investigation, reduction of L-dopa induced oxidative toxicity in mouse models was observed after treatment with *Lavandula angustifolia*<sup>25</sup>. Its aqueous extract has protective effects against glutamine-induced neurotoxicity in cell culture<sup>19</sup>. It was shown that lavender extract was effective in alleviating agitated behaviors in Chinese patients with dementia as an adjunctive therapy<sup>22</sup>. Several observations suggested that lavender extract may exert its physiological effects through disturbing dopaminergic neurotransmission<sup>26</sup>. Dopamine has important roles in brain functions, including locomotor activity, cognition, and emotion. Two recent studies revealed that lavender oil inhalation can improve scopolamine-induced memory impairment and dementia in the laboratory, male Wistar rats<sup>27,28</sup>. A recent study has investigated the effects of lavender floral water on the regulation of autonomic nervous system and reducing stress<sup>29</sup>. Re-

cently, Lavender extract has been shown to have the potential in clearing A $\beta$  from AD rat hippocampus<sup>30-32</sup>. In the current study, therapeutic effects of the lavender aqueous extract on rat Alzheimer's models are investigated. Serum samples were collected from animals and metabolic fingerprinting was done by NMR methods to search for affected metabolic pathways during the herbal therapy.

## Materials and Methods

### Preparation of lavender extract

The aerial parts of *Lavandula Angustifolia* including flowers were collected in August 2015. A voucher was deposited at the Medicinal Plants and Drugs Research Institute (MPDRI), Shahid Beheshti University of Medical Sciences, Tehran, Iran, with the herbarium number 1092. The taxonomic identity of the plant was further confirmed by the institute's botanist. Aqueous extract of *Lavandula angustifolia* was achieved according to Soheili M *et al*<sup>33</sup>. Briefly, flowers were air dried and weighed and placed into glass bottles. 250 gr of the dried flowers were mixed with 1 L of boiling water and stirred for 4 hr. The supernatant was collected by filtering through Whatman 3 mm filter paper. The filtrate was concentrated by vaporization.

### Animals

A total of 40 adults, male Wistar rats weighing 250-300 gr were employed. This study was approved by the ethical committee of Shahid Beheshti University of Medical Sciences. Treatment of the animals was in accordance with the policy of guide to the care and use of laboratory animals (NIH). The rats were kept in temperature controlled rooms under a 12 hr/12 hr light/dark cycle with access to water and food during the experiment. Wistar rats were randomly divided into the following 3 groups: 1- Normal controls (n=20), 2- Amyloid beta injected, as the Alzheimer's group (n=10), and 3- Amyloid beta injected with a following treatment with an aqueous lavender extract (n=10). Animal models of Alzheimer's disease were created according to the procedure of Zali H *et al*<sup>34</sup>. Briefly, the animals were anesthetized with a combination of 100 and 5 mg/kg *i.p.* of ketamine and xylazine. The fresh powder of amyloid beta 1-42 mixed with 200 microliter of distilled water and incubated at 37 °C for 7 days was used to create a fibrillar form of the peptide. The fibrillar form of amyloid beta 1-42 (Sigma Aldrich, St. Louis, MO, USA) was injected intracerebroventricularly (*i.c.v.*) 20 days before extract administration. The injection site (AP=Bregma, LR=1.5 mm, D=4 mm) was determined according to the Stereotaxic Atlas. The control animals were treated with the same procedure, except that they received distilled water. Alzheimer's rats were treated with aqueous extract of lavender 20 days after the establishment of Alzheimer's models. The optimum dosage of the aqueous extract was 200 mg per kg according to our previous studies<sup>33-35</sup>. The extract was injected once each day for

20 days at a volume of 0.4 ml/kg body weight. Morris Water Maze (MWM) was used as the screening test. The results of the MWM test have been published previously<sup>33</sup>.

#### **Serum sample preparation**

Blood samples were collected by cardiac puncture. They were then remained 20 min in the refrigerator and centrifuged at 3000 rpm for 10 min at 4°C to separate the serum. The serum samples were kept in -80°C freezer until analysis.

#### **Instrumentation**

The 1H-NMR analysis was the method of choice, on a Bruker DRX500 MHz spectrometer, equipped with 5 mm triple resonance inverse detection probe. 200 µl of D2O (99.9%, Sigma-Aldrich), was added to 300 µl of serum samples for the analysis. The chemical shifts of the samples were referenced to DSS (3-(Trimethylsilyl)-1-propanesulfonic acid-d6 sodium salt, 98% D, Sigma-Aldrich), as the standard, with peaks at 3.1 ppm (triplet), 1.9 ppm (pentet), and 0.8 ppm (triplet) at an intensity of 22% of the reference peak at 0.0 ppm. To reduce the broad signals of high molecular weight compounds, Carr-Parcell-Meibomian-Gill (CPMG) spin echo pulse with spin echo sequence  $\pi/2$ -tD- $\pi$ -tD was carried out. Acquisition parameters included spectral width 8,389.26 Hz, relaxation delay 2 s, time domain points 32 k, scan number of 154, spectrum size 32 k, and acquisition time of 1.95 s. An exponential line broadening function of 0.3 Hz was applied to free induction decay prior to Fourier transformation. All the spectra were manually phase- and baseline-corrected using XWINNMR software (Bruker Spectro-spin Ltd.).

#### **Data analysis**

For the processing of the NMR spectra, ProMetab software (version 3\_3), was used which works under the MATLAB environment (version 8.1.0.604, Mathworks, Cambridge, UK). The spectrum was divided into equal regions with the bucket size of 0.01 ppm, which yielded 813 spectral integral regions between 0.2 to 10 ppm. Signals related to presaturation of water resonance in the range of 4.5 to 5.5 were also removed. The spectra were normalized to reduce variations in sample concentrations. Multivariate statistical analyses, including Principal Component Analysis (PCA) and Partial Least Square-Discriminant Analysis (PLS-DA), were used to find significantly altered metabolites and to introduce a predictive model. The data processing and modeling were executed by the "Tool for statistical analysis on Microsoft Excel" which is a macros written by visual basic and is freely available at <http://prime.psc.riken.jp/><sup>36</sup>. The 3D PCA and PLS-DA diagrams were plotted in R. The ROC curve is plotted using SPSS 16.0.

#### **Metabolite identification**

The spectral bins of the highest importance according to Variable Importance in Projection (VIP) values were selected and the p-value and fold-change were

calculated for each. Those bins with VIP values of more than 1.4, the p-value < 0.05 and the fold change of more than 1.4 were brought to Biological Magnetic Resonance Data Bank (BMRB)<sup>37</sup> for identification. Significantly altered metabolites were found with the matching of the selected NMR spectral bins with the available data in metabolomics database BMRB, with an accuracy of  $\pm 0.05$  ppm.

#### **Metabolic pathway analysis**

Pathway analysis was performed to introduce affected metabolic pathways in Alzheimer and lavender treated groups using the web server, Metaboanalyst (<http://www.metaboanalyst.ca/>)<sup>38-40</sup>. Pathway analysis was done by searching the database for *Rattus norvegicus* by hypergeometric overrepresentation test and topological analysis with the relative betweenness centrality method. The most significant pathways were selected according to their p-values and impact values calculated from topology analyses.

## **Results**

#### **Multivariate statistical analysis**

As mentioned, processing of the NMR spectra was done by the ProMetab software. The result was a matrix including normalized spectral bins corresponding to different metabolites and the observations. The data were log10 transformed, and scaled by pareto method. Multivariate data analysis was performed on data matrix to find metabolites that mostly discriminated the groups, as potential biomarkers. A RIKEN platform in Microsoft Excel was used for the multi-variate analysis. Principal Component Analysis (PCA) was used as an unsupervised multivariate method. PCA is used for dimension reduction of data through making a linear combination of variables known as principal components and shows data structure as score and loadings plot. PCA analysis could reveal trends and groups of observations and find outliers. The variation which was explained by the first three components in PCA plots were 54.75, 11.87 and 8.7% for discriminating Alzheimer and control groups and 40.12, 23.57 and 9.7% for discriminating lavender-treated and Alzheimer groups. It was obviously observed in PCA plots that the two biological replicates in each comparison were well clustered together.

Partial Least Square-Discriminant Analysis (PLS-DA), was the supervised regression method to find potential metabolite markers in Alzheimer and treated groups. PLS can find the variables which cause significant variations between clusters. It also demonstrates the goodness of separation between classes. A seven-fold cross-validation was used to calculate Q2 value for the model. Q2 displays the cumulative percent of variation in Y-matrix which was predicted by the model based on 7-fold cross-validation. The cumulative Q2 values of PLS-DA model was 0.803 in Alzheimer vs. control and 0.896 in treated vs. Alzheimer groups which demonstrated the model's good predictive ability. The

## Metabolomics of Lavender Effect on Alzheimer




Figure 1. 3D scatter scores plots for A) PCA and B) PLS-DA models for the comparison of Alzheimer rats versus control group. As can be seen, PLS-DA model could obviously discriminate Alzheimer and control groups. Part C presents the Y observed versus Y predicted and the resulting ROC curve with AUC of 1 after 7-fold cross-validation of the PLS-DA model which confirms the model has well separated the groups.

Root Mean Square Error (RMSE) values for these comparisons were 0.1455 and 0.0993, respectively. Figures 1 and 2 present the 3D scatter scoreplots for PCA and PLS-DA, since the model was constructed based on the three first components. Figures 1 and 2 part C, show Y "observed" versus Y "predicted" and the resulting Receiver Operating Characteristic (ROC) curve for the PLS-DA models. The Area Under the Curve (AUC) was 1 for both groups which shows the high accuracy of the model for the separation of classes.

### Selection of biomarkers

The VIP values extracted from the PLS-DA models were used to find the most significantly altered metabolites. VIP ranks the variables based on their contribution to the model. Metabolites with VIP values of more than 1.4,  $p < 0.05$  and fold-change of more than 1.4 were selected. Discriminating metabolite markers are presented in table 1. As can be seen, the most important metabolite markers for the Alzheimer group included alanine, glutamine, serine, valine, isobutyrate, carnitine, taurine, pantothenate, glucose, asparagine, succinate, glycine, creatinine, isoleucine, pyruvate, betaine, choline, scyllo-inositol and myo-inositol. Mark-

ers of lavender extract administration included alanine, glutamine, serine, valine, isobutyrate, glucose, carnitine, isoleucine, pantothenate, asparagine, trimethylamine, glycolate, methionine, citrate and acetate.

### Metabolic pathway analysis

To elucidate the Alzheimer's related pathways and also mechanisms of action of the lavender extract on the rat models of AD, biochemical pathways were investigated using Metaboanalyst-3 server<sup>38-40</sup> which combines the results of pathway enrichment analysis and pathway topology to find the most relevant metabolic pathways. The most important pathways in Alzheimer's disease included glycine, serine and threonine metabolism, alanine, aspartate and glutamate metabolism, aminoacyl-tRNA biosynthesis, methane metabolism, valine, leucine and isoleucine metabolism, pantothenate and CoA metabolism, TCA cycle, and cysteine and methionine metabolism. The most significant pathways related to lavender administration in rats also included aminoacyl-tRNA biosynthesis, alanine, aspartate and glutamate metabolism, pantothenate and CoA metabolism, glyoxilate and dicarboxylate metabolism, cysteine and methionine metabolism. The detailed results are shown in table 2.






Figure 2. 3D scatter scores plots for A) PCA and B) PLS-DA models for the comparison of lavender treated rats versus Alzheimer group. Part C, shows the Yobserved versus Ypredicted and the resulting ROC curve with AUC of 1 after 7-fold cross-validation of the PLS-DA model. The groups are well separated by the model.

### Discussion

Rat models of AD are applicable in the study and modeling of the mechanisms responsible for the pathogenesis of the human disease<sup>3</sup>. Various drugs are currently used for the treatment of AD. In recent years, attentions are drawn to the use of herbal medicine in the treatment of cognitive impairments<sup>11,12</sup>. The Lavender extract has been shown to have therapeutic effects such as anticonvulsant, sedative, analgesic, antioxidant and local anesthetic activity<sup>18</sup>. It has been recently revealed that Lavender extract has the ability of clearing A $\beta$  plaques from AD rat hippocampus<sup>30</sup>. Thus, the effects of aqueous extracts of lavender on the improvement of memory and cognition were examined in A $\beta$ -induced rat Alzheimer's models through metabolomics investigations of the serum, utilizing Nuclear Magnetic Resonance (NMR) spectroscopy. NMR has the advantage of high repeatability and the wide range of identifying metabolites. Moreover, significant metabolites which were discovered in AD models compared to healthy controls could serve as a potential marker panel for detection of AD.

Serum metabolite profiles of 3 groups of rats (control, AD, and AD treated with lavender extract) were compared and significantly altered metabolites between the groups were identified which are presented

in table 1. The extract-treated AD rats showed memory and cognitive abilities improvements revealed by Morris-Water-Maze test. The MWM test results have been published elsewhere<sup>33</sup>. The treated group had also reversed direction of changes in some of metabolites levels, including alanine, glutamine, serine, glucose, asparagine, isoleucine, valine, carnitine, isobutyrate and pantothenate compared to AD group which showed the effectiveness of the lavender extract on the improvement of AD rats.

Seeking for the mechanisms of action of the herbal extract, biochemical pathways corresponding to altered metabolites were found using the Metaboanalyst online server. This platform uses KEGG metabolic pathways as the knowledge-based, integrating univariate and over-representation analyses and also novel algorithms such as global test, global Ancova and network topology in the pathway analysis. The altered metabolic pathways mostly belonged to amino acids and carbohydrate metabolism, including alanine, aspartate and glutamate metabolism, pantothenate and CoA metabolism, glyoxilate and dicarboxylate metabolism, cysteine and methionine metabolism. The main alterations in AD pathogenesis are related to energy metabolism, through different pathways such as TCA cycle, glycolysis, and amino acid metabolism, and also dysfunction

## Metabolomics of Lavender Effect on Alzheimer

Table 1. Metabolite markers for the Alzheimer and lavender treated rats extracted from PLS-DA model. Those metabolites which had VIP values >1.4, p-value < 0.05 and fold-change > 1.4 have been considered. (\*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001)

Metabolite name	BMRB ID	Alzheimer vs. control			Treated vs. alzheimer		
		VIP value	Fold change	p-value	VIP value	Fold change	p-value
1 Alanine	bmse000282	1.622	9	0.0134 *	1.922	0.164	0.00005 ***
2 Glutamine	bmse000038	1.470	2.6	0.0008 ***	1.605	0.4	0.0094 **
3 Serine	bmse000048	1.910	0.47	0.0011 **	1.724	1.42	0.0002 ***
4 Valine	bmse000052	2.750	3.88	0.0004 ***	2.601	0.48	0.0019 **
5 isobutyrate	bmse000439	1.661	0.6	0.0095 **	1.423	1.4	0.0025 **
6 Carnitine	bmse000211	1.789	3.1	0.0005 ***	1.558	0.43	0.0035 **
7 Pantothenate	bmse000287	1.910	0.47	0.0011 **	1.724	1.4	0.0002 ***
8 Glucose	bmse000015	2.132	2	0.0001 ***	2.763	0.4	0.00003 ***
9 Asparagine	bmse000030	1.900	0.45	0.001 **	1.526	3.48	0.0081 **
10 Isoleucine	bmse000041	1.474	0.6	0.0217 *	1.424	1.44	0.0025 **
11 succinate	bmse000183	1.661	0.62	0.0095 **	-	-	-
12 Glycine	bmse000089	1.427	1.4	0.0011 **	-	-	-
13 Creatinine	bmse000155	1.472	0.6	0.0068 **	-	-	-
14 Pyruvate	bmse000112	2.060	0.47	0.0002 ***	-	-	-
15 Betaine	bmse000069	1.699	2.6	0.0042 **	-	-	-
16 Choline	bmse000285	1.472	0.6	0.0068 **	-	-	-
17 Scyllo-inositol	bmse000113	1.699	2.57	0.0042 **	-	-	-
18 Myo-inositol	bmse000103	1.427	1.4	0.0011 **	-	-	-
19 Taurine	bmse000120	1.655	1.64	0.0002 ***	-	-	-
20 Trimethylamine	bmse000224	-	-	-	1.603	2.44	0.0038 **
21 Glycolate	bmse000245	-	-	-	1.806	1.6	0.00002 ***
22 Methionine	bmse000044	-	-	-	2.172	1.7	0.0002 ***
23 Citrate	bmse000076	-	-	-	1.958	6.5	0.0005 ***
24 Acetate	bmse000191	-	-	-	2.596	0.48	0.0004 ***

in mitochondrial activities. Impairments in energy metabolism were indicated by alterations in serum levels of glucose, glycine, serine, asparagine, succinate and isobutyrate. Impairments of TCA cycle enzymes and decreased levels of pyruvate dehydrogenase complex,  $\alpha$ -ketoglutarate dehydrogenase complex, isocitrate dehydrogenase, and malate dehydrogenase had been reported in AD <sup>41</sup>. Alterations in TCA cycle intermediate levels have also been previously shown in AD <sup>42</sup>.

A previous study demonstrated that high serum glucose levels are associated with cerebral hypometabolism in brain AD regions <sup>43</sup>. Another study described shared mechanisms between type 2 diabetes and AD, especially in glucose homeostasis <sup>44</sup>. In our study, asparagine level has decreased in AD group which is along with previous studies which indicates energy imbalance has occurred in the disease. The decrease of TCA cycle metabolites such as succinate is also because of mitochondrial impairments which lead to energy deficiency <sup>45,46</sup>. Changes in acetate concentration has also occurred in AD pathogenesis. Ketone bodies such as acetoacetate,  $\beta$ -hydroxybutyrate, and their related compound, acetate, are used to produce energy via TCA cycle and conversion to acetyl coen-zyme A. It has been previously shown that AD mouse models consume ketone bodies to produce ATP during mitochondrial-related energy deficiency by the increased activity of oxoacid-CoA transferase 1 enzyme, which

leads to decreased  $\beta$ -hydroxybutyrate levels as a ketone body and increased levels of by-products of ketone body metabolism <sup>47</sup>.

One of the pathways related to carbohydrate metabolism is the inositol phosphate metabolism. Inositol phosphates such as myo-inositol and scyllo-inositol involve in various cellular functions including signaling processes, cell growth and differentiation, endocytosis, and apoptosis. Altered levels of myo-inositol are related to alterations in phosphatidyl inositol metabolism and dysfunction of the phosphoinositide signaling system. Increased activity of myo-inositol monophosphate was previously reported in AD patients' brains <sup>48</sup>. Altered homeostasis of myo-inositol in neurons leads to the accumulation of free myo-inositol in the serum <sup>49</sup>.

One of the altered metabolites in AD group was taurine. Taurine (2-aminoethane sulfonic acid), is a non-protein amino acid implicated in various biological functions in the human body which is non-essential in rodents but essential in humans. It is the most abundant free amino acid in the intracellular compartments of human and other animals and is also an end-product in the cysteine metabolism. It is isolated in small amounts from brain synaptosomes in the form of glutaurine, which acts as a neurotransmitter. It also stabilizes the plasma membrane and affects glutamate generation which is also a very important neurotransmitter. Tau-

Table 2. The result of pathway analysis using Metaboanalyst3, for Alzheimer's disease and also lavender-treated groups. The pathways with p-value&lt;0.05 and impact value of more than 0 were selected. (\*p&lt;0.05, \*\*p&lt;0.01, \*\*\*p&lt;0.001)

Metabolic pathway category	Pathway name	Metabolite matches	p-value		Impact	
			AD	Treated	AD	Treated
<b>Carbohydrate metabolism</b>						
	pantothenate and CoA metabolism	Pantothenate, Valine	0.011*	0.009**	0.02	0.02
	TCA cycle	Succinate, Pyruvate	0.02*	-	0.097	-
	glyoxylate and dicarboxylate metabolism	Glycolate, Citrate	-	0.01*	-	0.333
<b>Amino acid metabolism</b>						
	glycine, serine and threonine metabolism,	Serine, Choline, Glycine, Betaine, Pyruvate	1.64E-5***	-	0.534	-
	alanine, aspartate and glutamate metabolism	Alanine, Glutamine, Pyruvate, Succinate, Asparagine	1.05E-4***	0.0014**	0.149	0.149
	Valine, leucine and isoleucine metabolism	Valine, Pyruvate, Isoleucine	0.006**	-	0.333	-
	cysteine and methionine metabolism	Serine, Pyruvate, Methionine	0.038*	0.03*	0.044	0.117
<b>Genetic information processing</b>						
	aminoacyl-tRNA biosynthesis	Glutamine, Glycine, Valine, Serine, Alanine, Asparagine, Methionine	6.22E-4***	2.11E-5***	0.137	0.137
<b>Energy metabolism</b>						
	Methane metabolism	Glycine, Serine	0.004**	-	0.4	-

rine has physiological functions such as anti-inflammatory, osmolarity maintenance, antioxidant and detoxification activities which are associated with Alzheimer's pathogenesis<sup>50,51</sup>. Acetylcholine is a neurotransmitter with low amounts in AD patients. Taurine has been shown to be able to increase the acetylcholine level in the brain. Various researchers have shown the decreased amounts of taurine in advanced AD patients<sup>52</sup>.

Amino acid metabolism pathways were also altered during treatment of AD rat models including alanine, aspartate and glutamate metabolism and cysteine and methionine metabolism. Cystine is the major form of cysteine in physiological conditions, and a limiting factor in the glutathione biosynthesis. Reduced glutathione is an antioxidant in the brain, which protects the brain cells against oxidative stress and excitotoxicity of glutamate<sup>53</sup>. Alanine is the downstream of N-acetyl-aspartate which is an important neurotransmitter. It is commonly produced by amination of pyruvate by the enzyme alanine transaminase, which involves interconversion of alanine and pyruvate, and  $\alpha$ -ketoglutarate and glutamate. Alanine participates in cellular bioenergetics, lower levels of which in AD group demonstrates the energetic deficiency and hypometabolism in AD, which could be related to decreased carbohydrate metabolism and mitochondrial dysfunction<sup>54</sup>. Aspartate is also synthesized by the amination of oxaloacetate. It is converted to the asparagine by the enzyme asparagine synthase. Aspartate is involved in cellular signaling processes in different forms, including beta-alanine, adenylo-succinate, and arginino-succinate. Aspartate also acts as a brain neurotransmitter which activates NMDA receptors. Glutamate is a precursor for the synthesis of neurotransmitter GABA. It is also the

most abundant excitatory neurotransmitter in the human CNS. After releasing from synaptic vesicles, it will bind NMDA receptors for activating the cells. Altered glutamine level is related to neurotransmitter system<sup>55</sup>. Glycine, serine and threonine metabolism, also alters during AD pathogenesis. This pathway participates in the synthesis and breakdown of glycine, serine, threonine and cysteine. Glycine and cysteine are synthesized from serine. Glycine is an inhibitory neurotransmitter in the nervous system. In our study, altered levels of glycine, serine, betaine, choline and pyruvate were observed, which are related to this metabolic pathway. It has been recently demonstrated that betaine rescues neuron damage. In previous studies, it was shown that betaine attenuated Alzheimer pathological changes and memory deficits induced by homocysteine in AD rat models<sup>56</sup>. In another study, it was revealed that betaine could reduce A $\beta$  levels in the brain by altering amyloid precursor protein processing in N2a cell line and proposed that it could have a protective role in amyloid beta production<sup>57</sup>. L-serine levels were also decreased in our study. Previous investigations have studied the role of D-serine in the pathogenesis of AD<sup>58-60</sup>. They have shown that D-serine levels were elevated in hippocampus and parietal cortex in AD rat models. D-serine is produced from L-serine by the enzyme serine racemase which can be a cause of the decreased serum levels of L-serine as was observed in our study. Pantothenate and CoA metabolism was the other important metabolic pathway. Pantothenic acid is essential for the synthesis of neurotransmitter acetylcholine, decreased levels of which in our study demonstrated its role in AD pathogenesis. In a study of J. Cooper<sup>61</sup>, it was observed that altered levels of pantothenate occurred in a cohort of patients




Figure 3. 10 biomarkers levels were reversed nearly to control values after treatment with lavender extract. The Y-axis represents the relative peak intensities in NMR spectra (\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ).

with dementia and proposed that it could be related to dysregulation of the Sodium-Dependent Multivitamin Transporter (SMVT) across cell membranes in AD.

### Conclusion

To the best of our knowledge, this is the first study that investigated the therapeutic effects of lavender extract on the memory improvement in  $A\beta$ -induced rat models of Alzheimer's disease through NMR metabolic fingerprinting of the serum. As was observed by Morris-Water-Maze test, the aqueous lavender extract could successfully improve memory and cognitive abilities in AD rats. It was also observed that values of some metabolites in lavender-treated group, including alanine, glutamine, serine, isoleucine, valine, carnitine, isobutyrate, pantothenate, glucose and asparagine reversed to control values which proposed the effectiveness of the therapy (Figure 3). The mechanism of action of the treatment was elucidated through the identification of affected metabolic pathways using significantly altered metabolites between AD and lavender-treated AD groups. The most significantly affected pathways belonged to carbohydrate and amino acid metabolism, including alanine, aspartate and glutamate metabolism, pantothenate and CoA metabolism, glyoxylate and dicarboxylate metabolism, and cysteine and methionine metabolism, so it could be concluded that the lavender extract exerts its therapeutic effect by balancing energy metabolism and also the levels of neurotransmitters.

According to the study results, lavender extract could be introduced as an effective drug candidate for the treatment of AD. According to the need for biomarkers of AD specially in blood samples which has a less invasive method than collecting CSF fluid, also a serum metabolite marker panel was proposed for the detection of AD, including alanine, glutamine, serine, valine, isobutyrate, carnitine, taurine, pantothenate, glucose, asparagine, succinate, glycine, creatinine, isoleucine, pyruvate, betaine, choline, scyllo-inositol and myo-inositol. However, these metabolites are required to be validated and studied in large cohorts.

### Acknowledgement

We are thankful of Shahid Beheshti University of Medical Sciences, Faculty of Paramedical Sciences, Tehran, Iran, for their support. We are also grateful to Dr. Robert Davidson for sending the software, Pro-Metab 3.3.

### References

1. Kelley BJ, Petersen RC. Alzheimer's disease and mild cognitive impairment. *Neurol Clin* 2007;25(3):577-609.
2. Meng X, D'Arcy C. Education and dementia in the context of the cognitive reserve hypothesis: a systematic review with meta-analyses and qualitative analyses. *PLoS One* 2012;7(6):e38268.
3. Trushina E, Mielke MM. Recent advances in the application of metabolomics to Alzheimer's disease. *Biochim Biophys Acta* 2014;1842(8):1232-1239.
4. Chu H, Zhang A, Han Y, Lu S, Kong L, Han J, et al. Metabolomics approach to explore the effects of Kai-Xin-San on Alzheimer's disease using UPLC/ESI-Q-TOF mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2016;1015-1016:50-61.
5. Mattson MP. Pathways towards and away from Alzheimer's disease. *Nature* 2004;430(7000):631-669.
6. Lista S, Faltraco F, Prvulovic D, Hampel H. Blood and plasma-based proteomic biomarker research in Alzheimer's disease. *Prog Neurobiol* 2013;101-102:1-17.
7. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, et al. Proteome-based plasma biomarkers for Alzheimer's disease. *Brain* 2006;129(Pt 11):3042-3050.
8. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. *J Neurol Neurosurg Psychiatry* 1999;66(2):137-147.
9. Shen ZX. Brain Cholinesterases: II. The molecular and cellular basis of Alzheimer's disease. *Med Hypotheses* 2004;63(2):308-321.
10. Akhondzadeh S, Abbasi SH. Herbal medicine in the treatment of Alzheimer's disease. *Am J Alzheimers Dis Other Demen* 2006;21(2):113-118.
11. Feng L, Yue XF, Chen YX, Liu XM, Wang LS, Cao FR, et al. LC/MS-based metabolomics strategy to assess the amelioration effects of ginseng total saponins on memory deficiency induced by simulated microgravity. *J Pharm Biomed Anal* 2016;125:329-338.
12. Li N, Liu Y, Li W, Zhou L, Li Q, Wang X, et al. A UPLC/MS-based metabolomics investigation of the protective effect of ginsenosides Rg1 and Rg2 in mice with Alzheimer's disease. *J Ginseng Res* 2016;40(1):9-17.
13. Farrokhi Yekta R, Rezaie Tavirani M, Arefi Oskouie A, Mohajeri-Tehrani MR, Soroush AR. The metabolomics and lipidomics window into thyroid cancer research. *Biomarkers* 2017;22(7):595-603.
14. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, et al. Ginkgo biloba for preven-



- tion of dementia: a randomized controlled trial. *JAMA* 2008;300(19):2253-2262.
15. Razzaghi-Asl N, Ebadi A, Edraki N, Shahabipour S, Miri R. Fragment-based binding efficiency indices in bioactive molecular design: a computational approach to BACE-1 inhibitors. *Iran J Pharm Res* 2013;12(3):423-428.
  16. Dalilan S, Rezaei-Tavirani M, Nabiuni M, Heidari-Keshel S, Zamanian Azodi M, Zali H. Aqueous extract of Lavender *angustifolia* inhibits lymphocytes proliferation of Hodgkin's lymphoma patients. *Iran J Cancer Prev* 2013;6(4):201-208.
  17. Mantovani AL, Vieira GP, Wilson RC, Groppo M, Santos RA, Rodrigues V, et al. Chemical composition, antischistosomal and cytotoxic effects of the essential oil of *Lavandula angustifolia* grown in southeastern Brazil. *Rev Bras Farmacogn* 2013;23(6):877-884.
  18. Hajhashemi V, Ghannadi A, Sharif B. Anti-inflammatory and analgesic properties of the leaf extracts and essential oil of *Lavandula angustifolia* Mill. *J Ethnopharmacol* 2003;89(1):67-71.
  19. Büyükkokuroğlu ME, Gepdiremen A, Hacimüftüoğlu A, Oktay M. The effects of aqueous extract of *Lavandula angustifolia* flowers in glutamate-induced neurotoxicity of cerebellar granular cell culture of rat pups. *J Ethnopharmacol* 2003;84(1):91-94.
  20. Kageyama A, Ueno T, Oshio M, Masuda H, Horiuchi H. Antidepressant-like effects of an aqueous extract of Lavender (*Lavandula angustifolia* Mill.) in rats. *Food Sci Technol Res* 2012;18(3):473-479.
  21. Lehrner J, Marwinski G, Lehr S, Jöhren P, Deecke L. Ambient odors of orange and lavender reduce anxiety and improve mood in a dental office. *Physiol Behav* 2005;86(1-2):92-95.
  22. Lin PW, Chan WC, Ng BF, Lam LC. Efficacy of aromatherapy (*Lavandula angustifolia*) as an intervention for agitated behaviours in Chinese older persons with dementia: a cross-over randomized trial. *Int J Geriatr Psychiatry* 2007;22(5):405-410.
  23. Duda SC, Marghitas LA, Dezmirean D, Duda M, Margaoan R, Bobis O. Changes in major bioactive compounds with antioxidant activity of *Agastache foeniculum*, *Lavandula angustifolia*, *Melissa officinalis* and *Nepeta cataria*: effect of harvest time and plant species. *Ind Crops Prod* 2015;77(23):499-507.
  24. Bajalana I, Mohammadi M, Alaei M, Pirbalouti AG. Total phenolic and flavonoid contents and antioxidant activity of extracts from different populations of lavender. *Ind Crops Prod* 2016;87:255-260.
  25. Nikolova G, Karamalakova Y, Kovacheva N, Stanev S, Zheleva A, Gadjeva V. Protective effect of two essential oils isolated from *Rosa damascena* Mill. and *Lavandula angustifolia* Mill, and two classic antioxidants against L-dopa oxidative toxicity induced in healthy mice. *Regul Toxicol Pharmacol* 2016;81:1-7.
  26. Kim Y, Kim M, Kim H, Kim K. Effect of lavender oil on motor function and dopamine receptor expression in the olfactory bulb of mice. *J Ethnopharmacol* 2009;125(1):31-35.
  27. Hritcu L, Cioanca O, Hancianu M. Effects of lavender oil inhalation on improving scopolamine-induced spatial memory impairment in laboratory rats. *Phytomedicine* 2012;19(6):529-534.
  28. Hancianu M, Cioanca O, Mihasan M, Hritcu L. Neuroprotective effects of inhaled lavender oil on scopolamine-induced dementia via anti-oxidative activities in rats. *Phytomedicine* 2013;20(5):446-452.
  29. Lee YT. A study of the effect of lavender floral-water eye-mask aromatherapy on the autonomous nervous system. *Eur J Integr Med* 2016;8(5):781-788.
  30. Kashani MS, Tavirani MR, Talei SA, Salami M. Aqueous extract of lavender (*Lavandula angustifolia*) improves the spatial performance of a rat model of Alzheimer's disease. *Neurosci Bull* 2011;27(2):99-106.
  31. Zali H, Rezaei Tavirani M, Azizi Jalalian F, Khodarahmi R. Proteins expression clustering of Alzheimer disease in rat hippocampus proteome. *J Paramed Sci* 2013;4(3):111-118.
  32. Zamanian-Azodi M, Rezaei-Tavirani M, Heydari-Kashal S, Kalantari S, Dailian S, Zali H. Proteomics analysis of MKN45 cell line before and after treatment with Lavender aqueous extract. *Gastroenterol Hepatol Bed Bench* 2012;5(1):35-42.
  33. Soheili M, Salami M, Haghiri AH, Zali H, Tavirani MR. Aqueous extract of *Lavandula angustifolia* alter protein expression in Alzheimer rats. *J Rep Pharm Sci* 2014;3(1):1-9.
  34. Zali H, Zamanian-Azodi M, Rezaei Tavirani M, Akbarzadeh Baghban A. Protein drug targets of *Lavandula angustifolia* on treatment of rat Alzheimer's disease. *Iran J Pharm Res* 2015;14(1):291-302.
  35. Budantsev Alu, Kisliuk OS, Shul'govskii VV, Rykunov DS, Iarkov AV. [The brain in stereotaxic coordinates (a textbook for colleges)]. *Zh Vyssh Nerv Deiat Im I P Pavlova* 1993;43(5):1045-1051.
  36. Tsugawa H, Cajka T, Kind T, Ma Y, Higgins B, Ikeda K, et al. MS-DIAL: data-independent MS/MS deconvolution for comprehensive metabolome analysis. *Nat Methods* 2015;12(6):523-526.
  37. Ulrich EL, Akutsu H, Doreleijers JF, Harano Y, Ioannidis YE, Lin J, et al. BioMagResBank. *Nucleic Acids Res* 2008;36(Database issue):D402-408.
  38. Xia J, Psychogios N, Young N, Wishart DS. MetaboAnalyst: a web server for metabolomic data analysis and interpretation. *Nucleic Acids Res* 2009;37(Web Server issue):W652-660.
  39. Xia J, Mandal R, Sinelnikov IV, Broadhurst D, Wishart DS. MetaboAnalyst 2.0--a comprehensive server for metabolomic data analysis. *Nucleic Acids Res* 2012;40(Web Server issue):W127-133.
  40. Xia J, Sinelnikov IV, Han B, Wishart DS. MetaboAnalyst 3.0--making metabolomics more meaningful. *Nucleic Acids Res* 2015;43(W1):W251-257.
  41. Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified

- Alzheimer's disease. *Eur J Nucl Med Mol Imaging* 2009; 36(5):811-822.
42. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. *Ann Neurol* 2005;57(5):695-703.
  43. Burns CM, Chen K, Kaszniak AW, Lee W, Alexander GE, Bandy D, et al. Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions. *Neurology* 2013;80(17):1557-1564.
  44. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? *Br J Clin Pharmacol* 2011;71(3):365-376.
  45. Jiang N, Yan X, Zhou W, Zhang Q, Chen H, Zhang Y, et al. NMR-based metabolomic investigations into the metabolic profile of the senescence accelerated mouse. *J Proteome Res* 2008;7(9):3678-3686.
  46. Hu ZP, Browne ER, Liu T, Angel TE, Ho PC, Chan EC. Metabolomic profiling of TASTPM transgenic Alzheimer's disease mouse model. *J Proteome Res* 2012;11(12):5903-5913.
  47. Yao J, Hamilton RT, Cadenas E, Brinton RD. Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence. *Biochim Biophys Acta* 2010;1800(10):1121-1126.
  48. Shimohama S, Tanino H, Sumida Y, Tsuda J, Fujimoto S. Alteration of myoinositol monophosphatase in Alzheimer's disease brains. *Neurosci Lett* 1998;245(3):159-162.
  49. Ferreira IL, Resende R, Ferreiro E, Rego AC, Pereira CF. Multiple defects in energy metabolism in Alzheimer's disease. *Curr Drug Targets* 2010;11(10):1193-1206.
  50. Takasaki M, Satsu H, Shimizu M. Physiological significance of the taurine transporter and taurine biosynthetic enzymes in 3T3-L1 adipocytes. *BioFactors* 2004;21(1-4):419-421.
  51. Graham SF, Holscher C, Green BD. Metabolic signatures of human Alzheimer's disease (AD): 1H NMR analysis of the polar metabolome of post-mortem brain tissue. *Metabolomics* 2014;10(4):744-753.
  52. Birdsall TC. Therapeutic applications of taurine. *Altern Med Rev* 1998;3(2):128-136.
  53. Fonteh AN, Harrington RJ, Tsai A, Liao P, Harrington MG. Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects. *Amino Acids* 2007;32(2):213-224.
  54. González-Domínguez R, García-Barrera T, Gómez-Ariza JL. Application of a novel metabolomic approach based on atmospheric pressure photoionization mass spectrometry using flow injection analysis for the study of Alzheimer's disease. *Talanta* 2015;131:480-489.
  55. Lin AP, Shic F, Enriquez C, Ross BD. Reduced glutamate neurotransmission in patients with Alzheimer's disease -- an in vivo (13)C magnetic resonance spectroscopy study. *MAGMA* 2003;16(1):29-42.
  56. Chai GS, Jiang X, Ni ZF, Ma ZW, Xie AJ, Cheng XS, et al. Betaine attenuates Alzheimer-like pathological changes and memory deficits induced by homocysteine. *J Neurochem* 2013;124(3):388-396.
  57. Liu XP, Qian X, Xie Y, Qi Y, Peng MF, Zhan BC, et al. Betaine suppressed A $\beta$  generation by altering amyloid precursor protein processing. *Neurol Sci* 2014;35(7):1009-1013.
  58. Madeira C, Lourenco MV, Vargas-Lopes C, Suemoto CK, Brandão CO, Reis T, et al. d-serine levels in Alzheimer's disease: implications for novel biomarker development. *Transl Psychiatry* 2015;5:e561.
  59. Nagata Y, Borghi M, Fisher GH, D'Aniello A. Free D-serine concentration in normal and Alzheimer human brain. *Brain Res Bull* 1995;38(2):181-183.
  60. Hashimoto K, Fukushima T, Shimizu E, Okada S, Komatsu N, Okamura N, et al. Possible role of D-serine in the pathophysiology of Alzheimer's disease. *Prog Neuro-psychopharmacol Biol Psychiatry* 2004;28(2):385-388.
  61. Cooper JL. Biotin deficiency and abnormal pantothenic acid levels in dementia. *Alzheimers Dement* 2008;4(4):T638-T639.